FDA — authorised 20 June 2003
- Application: NDA021567
- Marketing authorisation holder: BRISTOL MYERS SQUIBB
- Local brand name: REYATAZ
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Reyataz in United States
FDA authorised Reyataz on 20 June 2003
Marketing authorisations
FDA — authorised 2 June 2014
- Application: NDA206352
- Marketing authorisation holder: BRISTOL MYERS SQUIBB
- Local brand name: REYATAZ
- Indication: POWDER — ORAL
- Status: approved
FDA
- Status: approved
Reyataz in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Reyataz approved in United States?
Yes. FDA authorised it on 20 June 2003; FDA authorised it on 2 June 2014; FDA has authorised it.
Who is the marketing authorisation holder for Reyataz in United States?
BRISTOL MYERS SQUIBB holds the US marketing authorisation.